BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) shares rose 3.4% on Friday . The company traded as high as $3.09 and last traded at $3.08, with a volume of 402,724 shares changing hands. The stock had previously closed at $2.98.

BCRX has been the subject of a number of recent research reports. Zacks Investment Research cut BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, April 11th. FBR & Co reiterated a “buy” rating and set a $6.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Wednesday, July 6th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Monday, May 9th. Finally, Jefferies Group upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a research report on Wednesday, June 1st. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $9.70.

The stock’s market cap is $226.97 million. The firm’s 50-day moving average is $3.04 and its 200-day moving average is $3.63.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Thursday, May 5th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.08. During the same period last year, the business posted ($0.21) EPS. The firm earned $4.82 million during the quarter, compared to analyst estimates of $5.42 million. The firm’s revenue for the quarter was down 29.4% on a year-over-year basis. On average, equities research analysts anticipate that BioCryst Pharmaceuticals Inc. will post ($1.06) earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in BCRX. Morgan Stanley raised its stake in shares of BioCryst Pharmaceuticals by 13.9% in the fourth quarter. Morgan Stanley now owns 103,804 shares of the biotechnology company’s stock valued at $1,071,000 after buying an additional 12,646 shares during the period. Jennison Associates LLC raised its stake in shares of BioCryst Pharmaceuticals by 1.8% in the fourth quarter. Jennison Associates LLC now owns 1,348,563 shares of the biotechnology company’s stock worth $13,917,000 after buying an additional 24,014 shares during the period. Finally, Globeflex Capital L P bought a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $1,241,000.

BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and advanced chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.